FGL2 and gastrointestinal stromal tumor: Imatinib induced FGL2 expression in GIST cell lines, and patients with FGL2‐negative GIST had substantially longer RFS when treated with 3 years of adjuvant imatinib than when treated with 1 year of imatinib.